Metformin in Alzheimer’s dementia Prevention (MAP)

29 Mar Metformin in Alzheimer’s dementia Prevention (MAP)

The purpose of this study is to understand whether metformin (Glucophage® XR), a medication used for diabetes treatment and prevention, can prevent a decline in memory and thinking abilities for people who are already having mild memory problems.

At the first study visit you would have tests of memory and thinking and have a blood sample taken.  If you are eligible you would start taking metformin or a placebo (looks like metformin but has no effects) every day. Half the participants will take metformin, the other half the placebo. 

 
You would come back every six months for two years to repeat the tests you had done at the beginning of the study.  

Study visits will be done in a safe manner in accordance with University of Washington COVID-19 Safety Protocols.

Participant Eligibility

To be eligible, you need to be:

1. Between the ages of 55 and 90
2. Have been diagnosed with mild cognitive impairment (a physician or health care provider has told you) OR you or your family have concerns about your memory.
3. Overweight
4. Have a relative, significant other, or friend that could accompany you to study visits or answer questions by phone
5. Not taking any prescription medications to improve your memory such as rivastigmine, donepezil, galantamine, or memantine 
6. Not taking any narcotics, opioids, anti-anxiety medications or other medications that can affect your thinking

People with diabetes, liver disease, or kidney disease are not eligible to participate.

Contact

Hanson Research Team
(206) 897-5393